Related Experiment Video
Updated: Aug 16, 2026
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells
F Fabbri1, G Brigliadori, P Ulivi
1Istituto Oncologico Romagnolo, Morgagni-Pierantoni Hospital, Via Forlanini 34, 47100 Forlì, Italy.
Abstract:
Nitric oxide-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs) are a promising class of compounds that cause cell cycle perturbations and induce apoptosis in cell lines from different tumors. We investigated the activity of a recently developed NO-NSAID (NCX 4040) in bladder cancer cell lines (HT1376 and MCR). Cells were treated with different drug concentrations for different exposure times. Cytostatic and cytocidal activity was tested by SRB assay and apoptosis was evaluated by TUNEL analysis, ANNEXIN V assay and fluorescence microscopy. To further investigate the cell death-inducing mechanisms of NCX 4040, we analyzed gp-170, caspase expression and mitochondrial membrane potential (Delta Psi) depolarization. NCX 4040 showed a striking cytocidal activity in both cell lines, reaching LC(50) at a 10-microM and 50-microM concentrations in HT1376 and in MCR cells, respectively, after an exposure of only 6 h followed by an 18-h washout. Apoptosis was triggered in up to 90% of cells and was associated with active caspase-3 expression and Delta Psi depolarization in both cell lines after a 6-h exposure. In conclusion, NCX 4040, which probably causes apoptosis via a mitochondrial-dependent mechanism, could prove to be a useful agent for improving bladder cancer treatment.
Insights
Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) show promise for bladder cancer. NCX 4040 effectively induced apoptosis and cell death in bladder cancer cell lines, suggesting its potential as a novel therapeutic agent.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) demonstrate efficacy in inducing apoptosis across various cancer cell lines.
- Bladder cancer remains a significant health concern, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To evaluate the cytostatic and cytocidal activity of a novel NO-NSAID, NCX 4040, in human bladder cancer cell lines (HT1376 and MCR).
- To elucidate the mechanisms underlying NCX 4040-induced cell death, including apoptosis and mitochondrial pathway involvement.
Main Methods:
- Cell lines (HT1376, MCR) were treated with varying concentrations of NCX 4040 for different durations.
- Cytotoxicity was assessed using the Sulforhodamine B (SRB) assay.
- Apoptosis was evaluated through TUNEL analysis, Annexin V staining, and fluorescence microscopy.
- Mechanisms of cell death were investigated by analyzing gp-170 expression, caspase activation, and mitochondrial membrane potential (ΔΨ) depolarization.
Main Results:
- NCX 4040 exhibited significant cytocidal effects in both HT1376 (LC50 at 10 µM) and MCR (LC50 at 50 µM) cells after 6 hours of exposure and an 18-hour washout.
- Apoptosis was induced in up to 90% of cells, accompanied by caspase-3 activation and mitochondrial membrane potential depolarization.
- These effects were observed after a short 6-hour drug exposure.
Conclusions:
- NCX 4040 demonstrates potent anti-cancer activity against bladder cancer cell lines.
- The drug likely induces apoptosis through a mitochondrial-dependent pathway.
- NCX 4040 holds potential as a valuable therapeutic agent for improving bladder cancer treatment outcomes.
